Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI

Current Opinion in Neurology

Volumn 27, Issue 3, 2014, Pages 260-270

  Wattjes, Mike P ^a   Barkhof, Frederik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

magnetic resonance imaging; multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy

Indexed keywords

CORTICOSTEROID; NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

CEREBRAL BLINDNESS; CEREBROSPINAL FLUID ANALYSIS; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DEMYELINATION; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DISEASE ACTIVITY; DISEASE COURSE; ELECTRON MICROSCOPY; GRAY MATTER; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MIDDLE CEREBELLAR PEDUNCLE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SEIZURE; SURVIVAL; SUSCEPTIBILITY WEIGHTED IMAGING; SYMPTOM; TREATMENT OUTCOME; WHITE MATTER LESION; BRAIN; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 84900474314     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000099     Document Type: Review

References (73)

1. Brew BJ, Davies NW, Cinque P, et al. Progressive multifocal leukoencephalo-pathy and other forms of JC virus disease. Nat Rev Neurol 2010; 6:667-679.
2. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9:425-437.
3. Tyler KL. The uninvited guest. JC virus infection of neurons in PML. Neurology 2003; 61:734-735.
4. Cinque P, Koralnik IJ, Gerevini S, et al. Progressive multifocal leukoencepha-lopathy in HIV-1 infection. Lancet Infect Dis 2009; 9:625-636.
5. Rommer PS, Zettl UK, Kieseier B, et al. Requirement for safety monitoring for approved MS therapies: an overview. Clin Exp Immunol 2014; 175:397-407.
6. Rudick R, Polman C, Clifford D, Miller D, et al. Natalizumab: bench to bedside and beyond. JAMA Neurol 2013; 70:172-182.
7. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10:745-758.
8. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366:1870-1880.
9. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18:143-152.
10. Blair NF, Brew BJ, Halpern JP. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology 2012; 78:507-508.
11. Lindå H, von Heijne A. Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol 2013; 4:11.
12. Blinkenberg M, Sellebjerg F, Leffers AM, et al. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. Mult Scler 2013; 19:1226-1229.
13. Ayzenberg I, Lukas C, Trampe N, et al. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy. J Neurol 2012; 259:1732-1733.
14. Manenti G, Altobelli S, Nezzo M, et al. Early magnetic resonance detection of natalizumab-related progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. Case Rep Radiol 2013; 2013:415873.
15. Mc Govern EM, Hennessy MJ. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab. J Neurol 2013; 260: 665-667.
16. Phan-Ba R, Belachew S, Outteryck O, et al. The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas? Neurology 2012; 79:1067-1069.
17. Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 2012; 83:224-226.
18. Yousry TA, Pelletier D, Cadavid D, et al. MRI pattern in natalizumab-asso-ciated progressive multifocal leukoencephalopathy. Ann Neurol 2012;72:779-787.
19. Richert N, Bloomgren G, Cadavid D, et al. Imaging findings for PML in natalizumab-treated MS patients. Mult Scler 2012; 18 (Suppl 4):27; 99.
20. Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2013; 19:1826-1840.
21. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013;80:1430-1438.
22. Mentzer D, Prestel J, Adams O, et al. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neu-rol Neurosurg Psychiatry 2012; 83:927-933.
23. Kuhle J, Gosert R, Bühler R, et al. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 2011; 77:2010-2016.
24. Bergui M, Bradac GB, Oguz KK, et al. Progressive multifocal leukoencepha-lopathy: diffusion-weighted imaging and pathological correlations. Neuro-radiology 2004; 46:22-25.
25. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354:924-933.
26. Takeda S, Yamazaki K, Miyakawa T, et al. Progressive multifocal leukoence-phalopathy showing extensive spinal cord involvement in a patient with lymphocytopenia. Neuropathology 2009; 29:485-493.
27. Bernal-Cano F, Joseph JT, Koralnik IJ. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol 2007; 13:474-476.
28. Bourre B, Lefaucheur R, Ahtoy P, et al. Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology 2013; 81:1966-1967.
29. Yeung J, Cauquil C, Saliou G, et al. Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology 2013; 80:1812-1813.
30. Herold TR, Jakl V, Graser A, Eibl-Lindner K. Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis. Clin Ophthalmol 2012; 6:1131-1133.
31. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006; 60:162-173.
32. Gheuens S, Wüthrich C, Koralnik IJ. Progressive multifocal leukoencephalo-pathy: why grey and white matter. Annu Rev Pathol 2013; 8:189-215.
33. Moll NM, Rietsch AM, Ransohoff AJ, et al. Cortical demyelination in PML and MS: similarities and differences. Neurology 2008; 70:336-343.
34. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, et al. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizu-mab. J Neuropathol Exp Neurol 2012; 71:604-617.
35. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9:438-446.
36. Lindå H, von Heijne A, Major EO, et al. Progressive multifocal leukoence-phalopathy after natalizumab monotherapy. N Engl J Med 2009; 361:1081-1087.
37. Dong-Si T, Richman S, Bloomgren G, et al. Survival and functional outcome in asymptomatic natalizumab-associated progressive multifocal leukoencepha-lopathy multiple sclerosis patients [abstract]. Mult Scler 2013; 19 (S1):P879.
38. Eisele P, Szabo K, Griebe M, et al. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy. J Neu-roimaging 2013. [Epub ahead of print]
39. Gheuens S, Smith DR, Wang X, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 2012; 78:1390-1393.
40. Wattjes MP, Verhoeff L, Zentjens W, et al. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? J Neurol Neurosurg Psychiatry 2013; 84:1176-1177.
41. Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management. Neurology 2012; 79:2258-2264.
42. Berger JR. Steroids for PML-IRIS. A double-edged sword. Neurology 2009; 72:1454-1455.
43. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 2012; 123:235-245.
44. Wüthrich C, Popescu BF, Gheuens S, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. J Neuropathol Exp Neurol 2013; 72:1043-1051.
45. Vennegoor A, Wattjes MP, van Munster ET, et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 2011; 76:574-576.
46. Seewann A, Vrenken H, van der Valk P, et al. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. Arch Neurol 2009; 66:601-609.
47. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361:1075-1080.
48. Boster AL, Nicholas JA, Topalli I, et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol 2013; 70:398-402.
49. Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77:1061-1067.
50. Lenhard T, Biller A, Mueller W, et al. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 2010; 75:831-833.
51. Du Pasquier RA, Corey S, Margolin DH. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003; 61:775-782.
52. Koralnik IJ, Wüthrich C, Dang X, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57:576-580.
53. Wütrich C, Dang X, Westmoreland S, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009; 65:742-748.
54. Schippling S, Kempf C, Büchele F, et al. JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol 2013; 74:622-626.
55. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76:1697-1704.
56. Dahlhaus S, Hoepner R, Chan A, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013; 84:1068-1074.
57. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia Univ Press; 1949. p. 196.
58. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452.
59. Rispens T, Vennegoor A, Wolbink GJ, et al. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler 2012; 18:899-901.
60. Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol 2014; 75:108-115.
61. Wattjes MP, Killestein J. PML after natalizumab discontinuation: few and true? Ann Neurol 2014; 75:462.
62. Boster A, Hreha S, Berger JR, et al. Progresive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol 2009; 66:593-599.
63. Wattjes MP, Barkhof F. High field MRI in the diagnosis of multiple sclerosis: high field-high yield? Neuroradiology 2009; 51:279-292.
64. Kilsdonk ID, de Graaf WL, Barkhof F, et al. Inflammation high-field magnetic resonance imaging. Neuroimaging Clin N Am 2012; 22:135-157.
65. Kilsdonk ID, Wattjes MP, Lopez-Soriano A, et al. Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. Eur Radiol 2014; 24:841-849.
66. Visser F, Wattjes MP, Pouwels PJ, et al. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 2012; 79:2000-2003.
67. Jander S, Turowski B, Kieseier BC. Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012; 18:1650-1652.
68. Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology 2013; 81:1654-1658.
69. Décard BF, Haghikia A, Tonnes C, et al. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy. Mult Scler 2013; 19:249-251.
70. Hradilek P, Zeman D, Tudik I, et al. Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis. Mult Scler 2014; 20:639-640.
71. Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis 2013; 57:849-852.
72. van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368:1658-1659.
73. Chalkley JJ, Berger JR. Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep 2013; 13:408.